Tau‐Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
Abstract
Tau neurofibrillary tangles (T) are the primary driver of downstream neurodegeneration (N) and subsequent cognitive impairment in Alzheimer's disease (AD). However, there is substantial variability in the T‐N relationship – manifested in higher or lower atrophy than expected for level of tau in a given brain region. The goal of this study was to determine if region‐based quantitation of this variability allows for identification of underlying modulatory factors, including polypathology.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 15, 2021
- Source ID
- 10.1002/ana.26233
Entities
People
- Bradford C. Dickerson
- David A. Wolk
- David J. Irwin
- Ilya M. Nasrallah
- Lauren Mccollum
- Long Xie
- Michael Dicalogero
- Michael Tran Duong
- Paul A. Yushkevich
- Robin De Flores
- Sandhitsu Das
- The Alzheimer’s Disease Neuroimaging Initiative*
- Xueying Lyu
Organizations
- Alzheimer's Disease Neuroimaging Initiative
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Johnson & Johnson
- Massachusetts General Hospital
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Caen Normandy
- University of Pennsylvania
- University of Southern California
- University of Tennessee